Umbilical cord blood transplants improve cancer survival rates across all races

An­oth­er Chi­na-US deal for As­traZeneca: The British drug­mak­er is pay­ing $40 mil­lion up­front to Al­lo­ri­on Ther­a­peu­tics to de­vel­op the com­pa­ny’s L858R mu­tat­ed al­losteric in­hibitor as

Vaccine doses given to U.S. toddlers outside the recommended age or timing intervals have decreased over time, but still don’t complete the vaccine series for